Metformin mitigates apoptosis in ischemic myocardium

Journal of Surgical Research

Volumn 192, Issue 1, 2014, Pages 50-58

  Elmadhun, Nassrene Y ^a   Sabe, Ashraf A ^a   Lassaletta, Antonio D ^a   Chu, Louis M ^a   Sellke, Frank W ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cardioprotection; Metabolic syndrome; Metformin; Myocardial ischemia

Indexed keywords

CASPASE 3; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; ANTIDIABETIC AGENT; CARDIOTONIC AGENT; FORKHEAD TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DRUG EFFECT; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; METABOLIC SYNDROME X; NONHUMAN; OSSABAW MINIATURE SWINE; PORCINE MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; UPREGULATION; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MINIPIG; MYOCARDIAL ISCHEMIA; PATHOLOGY; PIG;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; METFORMIN; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; SWINE; SWINE, MINIATURE;

EID: 84921755768     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.05.005     Document Type: Article

References (17)

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854.
2. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244.
3. Norhammar A, Lindback J, Ryden L, Wallentin L, Stenestrand U. Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish register of information and knowledge about Swedish heart intensive care admission. Heart 2007;93:1577.
4. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the prevention of restenosis with tranilast and its outcomes (presto) trial. Circulation 2004;109:476.
5. Alserius T, Hammar N, Nordqvist T, Ivert T. Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes. Am Heart J 2006;152:599.
6. El Messaoudi S, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol 2011;22:445.
7. Lassaletta AD, Chu LM, Robich MP, et al. Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia. Basic Res Cardiol 2012;107:243.
8. Elmadhun NY, Lassaletta AD, Chu LM, Sellke FW. Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome. J Thorac Cardiovasc Surg 2013;145:258. discussion 265-256.
9. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the AKT-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008;103:274.
10. Maiese K, Chong ZZ, Shang YC, Hou J. A "foxo" in sight: targeting foxo proteins from conception to cancer. Med Res Rev 2009;29:395.
11. Perrelli MG, Pagliaro P, Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species. World J Cardiol 2011;3:186.
12. Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. Embo J 2000;19:4310.
13. Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008;57:696.
14. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMPactivated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55:496.
15. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012;119:651.
16. Nagy N, Shiroto K, Malik G, et al. Ischemic preconditioning involves dual cardio-protective axes with p38mapk as upstream target. J Mol Cell Cardiol 2007;42:981.
17. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 2002;97:276.